Abstract: Techniques for visual software development are disclosed, including: (a) generating, by a visual code editor, (1) a data model of a plurality of code elements in a set of source code and (2) a kernel for execution of the set of source code; (b) based on a subset of the set of source code, the data model, and the kernel, generating an adjustable graphical user interface (GUI) form control; (c) presenting the adjustable GUI form control in alignment with the set of source code in a GUI of the visual code editor; and (d) responsive to user input in the GUI to adjust the adjustable GUI form control: (1) modifying the subset of source code and the data model according to the user input; (2) updating the presentation of the set of source code in the GUI to reflect the modified subset of source code; and (3) executing the modified set of source code, thereby updating variable values within the kernel.

Abstract: Techniques for visual software development are disclosed, including: generating, by a visual code editor, a data model of code elements in a set of source code; based on the data model, generating an adjustable graphical user interface (GUI) control corresponding to a subset of the set of source code; presenting the adjustable GUI control in a GUI of the visual code editor; and responsive to user input in the GUI to adjust the adjustable GUI control, modifying the set of source code according to the user input and executing the modified set of source code.

Abstract: This disclosure relates to new assay methods for analysis of RNA, e.g., from circulating tumor cells (CTCs), tumor-specific exosomes, or tumor-specific cell-free RNA, in a subject's blood sample to determine an expression level of one or more lineage markers in the blood sample, wherein the expression level of a specific one or more lineage markers is predictive of progression-free survival and overall survival for a specific anti-cancer treatment regimen in that subject.

Abstract: This disclosure relates to new assay methods for analysis of RNA, e.g., from circulating tumor cells (CTCs), tumor-specific exosomes, or tumor-specific cell-free RNA, in a subject's blood sample to determine an expression level of one or more lineage markers in the blood sample, wherein the expression level of a specific one or more lineage markers is predictive of progression-free survival and overall survival for a specific anti-cancer treatment regimen in that subject.

Abstract: This disclosure relates to new assay methods for analysis of RNA, e.g., from circulating tumor cells (CTCs), tumor-specific exosomes, or tumor-specific cell-free RNA, in a subject's blood sample to determine an expression level of one or more lineage markers in the blood sample, wherein the expression level of a specific one or more lineage markers is predictive of progression-free survival and overall survival for a specific anti-cancer treatment regimen in that subject.